Aneuploidy, but not Ki‐67 or EGFR expression, is associated with recurrences in basal cell carcinoma

Background:  Basal cell carcinoma (BCC), the most common skin cancer, has an overall excellent prognosis, but recurrences are frequent. The value of classical clinical and histological prognostic factors to predict recurrences remain limited.

[1]  K. Song,et al.  Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. , 2006, International journal of radiation oncology, biology, physics.

[2]  S. Chevillard,et al.  Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.

[3]  Å. Borg,et al.  Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas , 1991, Breast Cancer Research and Treatment.

[4]  Désirée Ratner,et al.  Current concepts : Basal-cell carcinoma , 2005 .

[5]  A. Coulomb.  Recommandations pour les carcinomes basocellulaires , 2004 .

[6]  A. Lavrijsen,et al.  Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell, carcinomas of the skin , 2004, Archives of Dermatological Research.

[7]  C. Liao,et al.  Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis , 2003, British Journal of Cancer.

[8]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[9]  B. Akkaya,et al.  Prognostic Value of Ki‐67, CD31 and Epidermal Growth Factor Receptor Expression in Basal Cell Carcinoma , 2003, The Journal of dermatology.

[10]  S. Lippman,et al.  p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  D. Kuijpers,et al.  Basal Cell Carcinoma , 2002, American journal of clinical dermatology.

[12]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[13]  G. Argenziano,et al.  DNA ploidy and cyclin D1 expression in basal cell carcinoma of the head and neck. , 2001, American journal of clinical pathology.

[14]  J. Utikal,et al.  Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. , 2001, European journal of cancer.

[15]  S. Fisher,et al.  Recurrent basal cell carcinoma after incomplete resection. , 2000, Archives of dermatology.

[16]  U. Brinck,et al.  Comparison of the DNA content in recurrent and nonrecurrent basaliomas of the face. , 1998, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[17]  A. Hoznek,et al.  The prognostic value of p53 nuclear overexpression and MIB‐1 as a proliferative marker in transitional cell carcinoma of the bladder , 1997, Cancer.

[18]  K. Smith,et al.  Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. , 1997, Journal of the American Academy of Dermatology.

[19]  E. Healy,et al.  Prognostic value of Ki67 antigen expression in basal cell carcinomas , 1995, The British journal of dermatology.

[20]  Y. Ro.  Oncogene interaction in basal cell carcinomas of human skin. , 1995, Journal of Korean medical science.

[21]  Stanley J. Miller,et al.  Biology of basal cell carcinoma (Part I). , 1991, Journal of the American Academy of Dermatology.

[22]  Stanley J. Miller,et al.  Biology of basal cell carcinoma (Part II). , 1991, Journal of the American Academy of Dermatology.

[23]  P. Dykes,et al.  Epidermal growth factor receptors in human epidermal tumours , 1990, The British journal of dermatology.

[24]  T. Nishikawa,et al.  Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours , 1990, The British journal of dermatology.

[25]  T. Bauknecht,et al.  [Determination of epidermal growth factor (EGF) receptors in basal cell carcinomas, squamous cell carcinomas and melanomas]. , 1990, Zeitschrift fur Hautkrankheiten.

[26]  T. Nishikawa,et al.  Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumors , 1990 .

[27]  R. Carroll,et al.  Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. , 1989, The Journal of dermatologic surgery and oncology.

[28]  O. Kallioniemi,et al.  Prognostic significance of dna index, multiploidy, and S‐phase fraction in ovarian cancer , 1988, Cancer.

[29]  M. Melamed,et al.  Flow cytometry of prostate cancer: relationship of DNA content to survival. , 1987, Cancer research.

[30]  T. Bauknecht,et al.  Epidermal growth factor receptors in different skin tumors. , 1985, Dermatologica.